Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.70 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 8/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361356 | 1.00 | TGFBR1 (0.70) | TGFBR1FEN1PDK2PIM1PDK1 | |
| SCHEMBL23218015 | 0.92 | TGFBR1 (0.59) | TGFBR1FEN1MAPK14 | |
| SCHEMBL5199498 | 0.90 | TGFBR1 (0.56) | TGFBR1PIM1MAPK14 | |
| SCHEMBL5198295 | 0.89 | TGFBR1 (0.56) | TGFBR1FEN1PIK3CA | |
| SCHEMBL24311917 | 0.89 | TGFBR1 (0.56) | TGFBR1PDK2PIM1MAPK14 | |
| SCHEMBL23218007 | 0.87 | TGFBR1 (0.54) | TGFBR1FEN1MAPK14 | |
| SCHEMBL5198228 | 0.87 | TGFBR1 (0.52) | TGFBR1FEN1PIM1MAPK14 | |
| SCHEMBL5200014 | 0.86 | TGFBR1 (0.53) | TGFBR1PIM1FGFR1DDR2PIK3CA | |
| SCHEMBL24311918 | 0.86 | TGFBR1 (0.53) | TGFBR1PIM1MAPK14 | |
| SCHEMBL24311947 | 0.86 | TGFBR1 (0.53) | TGFBR1PDK2PIM1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371664-B2 | Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby | CHA BIOTECH CO., LTD. (KR) | 2025-07-29 | — | — | US | claimed |
| US-12065671-B2 | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-20 | — | — | US | claimed |
| US-20240271089-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-15 | — | — | US | claimed |
| EP-4347795-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4345160-A2 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-03 | — | — | EP | claimed |
| CN-114807035-B | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2024-02-02 | — | — | CN | claimed |
| EP-3347456-B1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | US HEALTH (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2022251499-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-01 | — | — | WO | claimed |
| CN-114807035-A | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2022-07-29 | — | — | CN | claimed |
| CN-108473962-B | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2022-04-26 | — | — | CN | claimed |
| EP-3848455-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA Biotech Co., Ltd. (KR) | 2021-07-14 | — | — | EP | claimed |
| CN-112996903-A | Culture medium for directly differentiating pluripotent stem cell-derived mesenchymal stem cells, method for preparing mesenchymal stem cells by using culture medium and mesenchymal stem cells prepared by using culture medium | 车比奥泰有限公司 | 2021-06-18 | — | — | CN | claimed |
| US-20210139847-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-05-13 | — | — | US | claimed |
| US-20190169569-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-06-06 | — | — | US | claimed |
| EP-3347456-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2018-07-18 | — | — | EP | claimed |
| EP-3307874-A1 | DERIVATION OF HEPATIC STEM CELLS AND MATURE LIVER CELL TYPES AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2018-04-18 | — | — | EP | claimed |
| WO-2017044483-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-03-16 | — | — | WO | claimed |
| WO-2016200340-A1 | DERIVATION OF HEPATIC STEM CELLS AND MATURE LIVER CELL TYPES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-12-15 | — | — | WO | claimed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | TGFBR1 40/4885FEN1 4807/4885PDK2 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.